Akebia Therapeutics (AKBA) Interest Expenses (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Interest Expenses data on file, last reported at $3.5 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 69.0% year-over-year to $3.5 million in Q1 2026; TTM through Mar 2026 was $3.5 million, a 28.09% decrease from a year earlier, with the FY2025 full-year figure at $22.0 million, down 94.32% from the prior year.
• Interest Expenses for Q1 2026 stood at $3.5 million, up from $1.7 million in the prior quarter.
• Over the last five years, Interest Expenses for AKBA reached as high as $28.4 million in Q2 2025 and fell as low as -$745000.0 in Q4 2022.
• Historically, Interest Expenses has averaged $4.0 million across 5 years, with a median of $1.7 million in 2024.
• Across the five-year window, Interest Expenses tumbled 134.22% in 2024 and surged 1673.88% in 2025, its largest moves.
• Year by year, Interest Expenses stood at -$745000.0 in 2022, then surged by 282.42% to $1.4 million in 2023, then slumped by 134.22% to -$465000.0 in 2024, then surged by 461.29% to $1.7 million in 2025, then soared by 111.25% to $3.5 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $3.5 million in Q1 2026, $1.7 million in Q4 2025, and $15.2 million in Q3 2025.